Navigation Links
ProMetic provides business update - Over $35 million worth of business secured in January
Date:2/6/2008

- Shipment of prion capture resin to MacoPharma in Q1 2008; - MacoPharma increased its forecast for P-Capt(R) filters sale in 2008; - Use of affinity prion adsorbent for plasma-derived products to generate

in excess of $25 M over the next 5 years

- $4 M in 2008; - 10th product approved by the FDA and or the EMEA, contributing to revenue

growth.

MONTREAL, Feb. 6 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today provided an update on its business activities.

"Key milestones were achieved in January, a prelude to the announced growth for 2008 and beyond," stated Pierre Laurin, ProMetic's President and Chief Executive Officer. "With our Protein Technologies Business expected to be EBITDA positive this year, and to generate an EBITDA in excess of $15 M in 2009, as well as a partnering of PBI-1402 in 2008, we clearly are on track to deliver value to our shareholders," added Mr. Laurin.

- ProMetic to ship prion capture resin in Q1 2008 for incorporation into

the P-Capt(R) filter. This is in response to MacoPharma's increased

product requirements to meet the expected sales of the P-Capt(R) filter

to Ireland and the UK in 2008. This favorably impacts ProMetic revenue

as of the first half of 2008.

- ProMetic confirmed the decision of a major European plasma fractionator

to scale-up the prion removal process. This process ensures the removal

of any abnormal prion proteins that may be present in donated plasma

and will add another level of safety to the already established

treatment protocols.

- Expected completion of the scale-up phase is June 2008, providing

ProMetic approximately $1 M;

- Including Kedrion, this will signify two major European plasma

fractionators using the prion reduction resin at scal
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
2. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
3. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
4. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
5. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
6. YM BioSciences provides update on AeroLEF(TM) clinical development program
7. ViroPharma Provides 2008 Outlook
8. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
9. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
10. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
11. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
(Date:9/30/2014)... , Sept. 30, 2014 Report Details ... with highest potential revenues Do you want to ... gives you revenue predictions for those biological drugs ... therapies you find financial data, R&D trends, opportunities ... get sales forecasts to 2024 at overall world ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration ... budgets and increased acceptance of new filtration technologies in ... industries are also catalyzing the growth of laboratory filtration ... to grow at a strong CAGR during the forecast ... $2,532.6 million by 2019. The market is mainly driven ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... 29 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, announced today,that Guy L. ... the Roth Capital Partners New York Investor Conference on,Thursday, ... conference is,being held at The Westin NY at Times ...
... N.Y., Aug. 29 Emisphere,Technologies, Inc. (Nasdaq: ... been appointed to the position of Chief Financial ... CFO and Interim Chief Executive Officer,of Astralis, Ltd., ... Michael V. Novinski, President and Chief Executive Officer. ...
... PHRM ) today announced that the U.S. ... designation for oral Azacitidine in the,treatment of Myelodysplastic ... to facilitate the development and,expedite the review of ... or,life-threatening conditions and that demonstrate the potential to ...
Cached Biology Technology:Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
(Date:9/30/2014)... New England Journal of Medicine reports positive ... drug crizotinib against the subset of lung cancer marked ... study of 50 patients with advanced non-small cell lung ... rate was 72 percent, with 3 complete responses and ... it takes for the disease to resume its growth ...
(Date:9/30/2014)... in German . ... expensive foods in the world. Because they grow underground, people ... distinctive smell of truffles is not only of interest to ... direction of the Goethe University Frankfurt have discovered that the ... which are trapped inside truffle fruiting bodies. , White truffles ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2
... team of University of Washington undergraduate students was among ... one of the Bill & Melinda Gates Foundation,s $100,000 ... fifth round of Grand Challenges Explorations, an initiative to ... unproven ways to improve health in developing countries. To ...
... release is available in Spanish . , U.S. ... ways to improve soil on degraded land so it can ... with USDA,s Agricultural Research Service (ARS) at the agency,s Appalachian ... constructed or replacement subsoils and topsoils to build better and ...
... Albert Einstein College of Medicine of Yeshiva University researcher ... Honor in Basic Science from the American Cancer Society ... role the tumor microenvironment plays in modulating cancer behavior, ... cells called macrophages play both in normal development and ...
Cached Biology News:Undergraduates' low-cost ultrasound system wins Gates Foundation grant 2Undergraduates' low-cost ultrasound system wins Gates Foundation grant 3Improving soil for better lawns and gardens 2Einstein researcher receives American Cancer Society Medal of Honor 2
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: